Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 handwiki Rita Xu -- 2802 2022-11-08 01:34:41

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
HandWiki. Cannabinoid Receptor Antagonist. Encyclopedia. Available online: https://encyclopedia.pub/entry/33408 (accessed on 23 September 2026).
HandWiki. Cannabinoid Receptor Antagonist. Encyclopedia. Available at: https://encyclopedia.pub/entry/33408. Accessed September 23, 2026.
HandWiki. "Cannabinoid Receptor Antagonist" Encyclopedia, https://encyclopedia.pub/entry/33408 (accessed September 23, 2026).
HandWiki. (2022, November 08). Cannabinoid Receptor Antagonist. In Encyclopedia. https://encyclopedia.pub/entry/33408
HandWiki. "Cannabinoid Receptor Antagonist." Encyclopedia. Web. 08 November, 2022.
Cannabinoid Receptor Antagonist
Edit
The content is sourced from: https://handwiki.org/wiki/Chemistry:Cannabinoid_receptor_antagonist

A cannabinoid receptor antagonist, also known simply as a cannabinoid antagonist or as an anticannabinoid, is a type of cannabinoidergic drug that binds to cannabinoid receptors (CBR) and prevents their activation by endocannabinoids. They include antagonists, inverse agonists, and antibodies of CBRs. The discovery of the endocannabinoid system led to the development of CB1 receptor antagonists. The first CBR inverse agonist, rimonabant, was described in 1994. Rimonabant blocks the CB1 receptor selectively and has been shown to decrease food intake and regulate body-weight gain. The prevalence of obesity worldwide is increasing dramatically and has a great impact on public health. The lack of efficient and well-tolerated drugs to cure obesity has led to an increased interest in research and development of CBR antagonists. Cannabidiol (CBD), a naturally occurring cannabinoid, is a non-competitive CB1/CB2 receptor antagonist. And Δ9-tetrahydrocannabivarin (THCV), a naturally occurring cannabinoid, modulate the effects of THC via direct blockade of cannabinoid CB1 receptors, thus behaving like first-generation CB1 receptor inverse agonists, such as rimonabant. CBD is a very low-affinity CB1 ligand, that can nevertheless affect CB1 receptor activity in vivo in an indirect manner, while THCV is a high-affinity CB1 receptor ligand and potent antagonist in vitro and yet only occasionally produces effects in vivo resulting from CB1 receptor antagonism. THCV has also high affinity for CB2 receptors and signals as a partial agonist, differing from both CBD and rimonabant.

public health cannabinoid receptors cannabidiol

References

  1. Pertwee, R.G. (2006), "Cannabinoid pharmacology: the first 66 years", British Journal of Pharmacology 147 (S1): S163–S171, doi:10.1038/sj.bjp.0706406, PMID 16402100  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1760722
  2. Reggio, P.H. (2003), "Pharmacophores for Ligand Recognition and Activation/Inactivation of the Cannabinoid Receptors", Current Pharmaceutical Design 9 (20): 1607–1633, doi:10.2174/1381612033454577, PMID 12871061, http://science.kennesaw.edu/projects/cab/CurPharmDes-Reggio-2003.pdf 
  3. Schlesinger S. Untersuchung der Cannabis sativa. Repertorium für die Pharmacie. 1840:190-208.
  4. Decourtive E. Note sur le haschisch. CR Hebd Séances Acad Sci..1848;26:509-510.
  5. "Archived copy". http://www.dialogues-cns.com/brochures/35/pdf/35.pdf#page=61. 
  6. Howlett, A.C.; Breivogel, C.S.; Childers, S.R.; Deadwyler, S.A.; Hampson, R.E.; Porrino, L.J. (2004), "Cannabinoid physiology and pharmacology: 30 years of progress", Neuropharmacology 47: 345–358, doi:10.1016/j.neuropharm.2004.07.030, PMID 15464149  https://dx.doi.org/10.1016%2Fj.neuropharm.2004.07.030
  7. Patel, P.N.; Pathak, R. (2007), "Rimonabant: A novel selective cannabinoid – 1 receptor antagonist for treatment of obesity", American Journal of Health-System Pharmacy 64 (5): 481–489, doi:10.2146/060258, PMID 17322160  https://dx.doi.org/10.2146%2F060258
  8. Barth, F.; Rinaldi-Carmona, M. (1999), "The Development of Cannabinoid Antagonists", Current Medicinal Chemistry 6 (8): 745–755, PMID 10469889, http://www.bentham.org/cmc/contabs/vol6-8.html 
  9. Mackie K (2006), "Cannabinoid receptors as therapeutic targets", Annu. Rev. Pharmacol. Toxicol. 46: 101–22, doi:10.1146/annurev.pharmtox.46.120604.141254, PMID 16402900, http://www.safeaccessnow.org/downloads/Mackie%20CB%20Receptors%20Annur%20Rev%20Pharm%20Tox%202006.pdf. 
  10. Fong TM, Heymsfield SB (September 2009), "Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions", Int J Obes (Lond) 33 (9): 947–55, doi:10.1038/ijo.2009.132, PMID 19597516.  https://dx.doi.org/10.1038%2Fijo.2009.132
  11. Svíženská, I.; Dubový, P.; Šulcová, A. (2008), "Cannabinoid receptor 1 and 2 ( CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures – A short review", Pharmacology Biochemistry and Behavior 90 (4): 501–511, doi:10.1016/j.pbb.2008.05.010, PMID 18584858  https://dx.doi.org/10.1016%2Fj.pbb.2008.05.010
  12. Xie, S.; Furjanic, M.A.; Ferrara, J.J.; McAndrew, N.R.; Ardino, E.L.; Ngondara, A.; Bernstein, Y.; Thomas, K.J. et al. (2007), "The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use", Journal of Clinical Pharmacy and Therapeutics 32 (3): 209–231, doi:10.1111/j.1365-2710.2007.00817.x, PMID 17489873  https://dx.doi.org/10.1111%2Fj.1365-2710.2007.00817.x
  13. Ashton, J.S.; Wright, J.L.; McPartland, J.M.; Tyndall, J.D.A. (2008), "Cannabinoid CB1 and CB2 Receptor Ligand Specificity and the Development of CB2-Selective Agonists", Current Medicinal Chemistry 15 (14): 1428–1443, doi:10.2174/092986708784567716, PMID 18537620  https://dx.doi.org/10.2174%2F092986708784567716
  14. Di Marzo, V. (2008), "CB1 receptor antagonism: biological basis for metabolic effects", Drug Discovery Today 13 (23–24): 1–16, doi:10.1016/j.drudis.2008.09.001, PMID 18824122  https://dx.doi.org/10.1016%2Fj.drudis.2008.09.001
  15. Rinaldi – Carmona, M.; Barth, F.; Héaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J. et al. (1994), "SR141716A, a potent and selective antagonist of the brain cannabinoid receptor", FEBS Letters 350 (2–3): 240–244, doi:10.1016/0014-5793(94)00773-X, PMID 8070571  https://dx.doi.org/10.1016%2F0014-5793%2894%2900773-X
  16. Muccioli, G.G.; Lambert, D.M. (2005), "Current Knowledge on the Antagonists and Inverse Agonists of Cannabinoid Receptors", Current Medicinal Chemistry 12 (12): 1361–1394, doi:10.2174/0929867054020891, PMID 15974990, http://www.farm.ucl.ac.be/Full-texts-FARM/Muccioli-2005-2.pdf 
  17. Ortega-Gutiérrez, S.; López-Rodriguez, M.L. (2005), "CB1 and CB2 Cannabinoid Receptor Binding Studies Based on Modeling and Mutagenesis Approaches", Mini-Reviews in Medicinal Chemistry 5 (7): 651–658, doi:10.2174/1389557054368754, PMID 16026311  https://dx.doi.org/10.2174%2F1389557054368754
  18. Lange, Jos H.M.; Kruse, Chris G. (2005), "Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists", Drug Discovery Today 10 (10/24): 693–702, doi:10.1016/S1359-6446(05)03427-6, PMID 15896682  https://dx.doi.org/10.1016%2FS1359-6446%2805%2903427-6
  19. McAllister, S.D.; Rizvi, G.; Anavi-Goffer, S.; Hurst, D.P.; Barnett-Norris, J.; Lynch, D.L.; Reggio, P.H.; Abood, M.E. (2003), "An Aromatic Microdomain at the Cannabinoid CB1 Receptor Constitutes an Agonist/Inverse Agonist Binding Region", Journal of Medicinal Chemistry 46 (24): 5139–5152, doi:10.1021/jm0302647, PMID 14613317  https://dx.doi.org/10.1021%2Fjm0302647
  20. Fan, H.; Kotsikorou, E.; Hoffman, A.F.; Ravert, H.T.; Holt, D.; Hurst, D.P.; Lupica, C.R.; Reggio, P.H. et al. (2008), "Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): Development of ligands with optimized lipophilicity and binding affinity", European Journal of Medicinal Chemistry 44 (2): 1–16, doi:10.1016/j.ejmech.2008.03.040, PMID 18511157  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2728551
  21. Foloppe, N.; Allen, N.H.; Bentlev, C.H.; Brooks, T.D.; Kennett, G.; Knight, A.R.; Leonardi, S.; Misra, A. et al. (2008), "Discovery of novel class of selective human CB1 inverse agonists", Bioorganic & Medicinal Chemistry Letters 18 (3): 1199–1206, doi:10.1016/j.bmcl.2007.11.133, PMID 18083560  https://dx.doi.org/10.1016%2Fj.bmcl.2007.11.133
  22. Jagerovic, N.; Fernandez – Fernandez, C.; Goya, P. (2008), "CB1 Cannabinoid Antagonists: Structure – Activity Relationships and Potential Therapeutic Applications", Current Topics in Medicinal Chemistry 8 (3): 205–230, doi:10.2174/156802608783498050, PMID 18289089  https://dx.doi.org/10.2174%2F156802608783498050
  23. "AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.", Neuropharmacology. 2012 Oct;63(5):905-15. doi: 10.1016/j.neuropharm.2012.06.046. Epub 2012 Jul 4. https://www.sciencedirect.com/science/article/pii/S0028390812003048?via%3Dihub
  24. Barth, F. (2005), "CB1 Cannabinoid Receptor Antagonists", Annual Reports in Medicinal Chemistry Volume 40, Annual Reports in Medicinal Chemistry, 40, pp. 103–118, doi:10.1016/S0065-7743(05)40007-X, ISBN 978-0-12-040540-4, http://www.elsevier.com/wps/find/bookdescription.cws_home/706482/description#description, retrieved 2008-11-14 
  25. Vemuri, V.K.; Janero, D.R.; Makriyannis, A. (2008), "Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome", Physiology & Behavior 93 (4–5): 671–686, doi:10.1016/j.physbeh.2007.11.012, PMID 18155257  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3681125
  26. Kim, M.; Yun, H.; Kwak, H.; Kim, J.; Lee, J. (2008), "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist", Tetrahedron 64 (48): 10802–10809, doi:10.1016/j.tet.2008.09.057  https://dx.doi.org/10.1016%2Fj.tet.2008.09.057
  27. Barchukov, V. V.; Zhavbert, E. S.; Dugina, Yu. L.; Epstein, O. I. (2015). "The Use of Release-Active Antibody-Based Preparations for Vertigo Prevention in Adults". Bulletin of Experimental Biology and Medicine 160 (1): 61–63. doi:10.1007/s10517-015-3098-z. ISSN 0007-4888. PMID 26608378.  https://dx.doi.org/10.1007%2Fs10517-015-3098-z
  28. [1]
  29. "Sanofi, a global biopharmaceutical company focused on human health - Sanofi". http://en.sanofi-aventis.com/binaries/20081105_rimonabant_en_tcm28-22682.pdf. 
  30. http://www.sanofi-aventis.ca/live/ca/medias/DA924A61-8E54-4D1D-B1FB-71C953E398C2.pdf
  31. "Archived copy". http://www.merck.com/newsroom/press_releases/research_and_development/2008_1002_print.html. 
  32. http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp?rssUrl=http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1010794&newsId=20081105006339&newsLang=en
  33. Chorvat, Robert J. (2013). "Peripherally restricted CB-1 receptor blockers". Bioorg. Med. Chem. Lett. 23 (17): 4751–4760. doi:10.1016/j.bmcl.2013.06.066. PMID 23902803.  https://dx.doi.org/10.1016%2Fj.bmcl.2013.06.066
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Chemistry, Applied
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
HandWiki
View Times: 2.3K
Entry Collection: HandWiki
Revision: 1 time (View History)
Update Date: 08 Nov 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback